- Q2-2018 ·
Frost & Sullivan Independent Equity Research
Cellect. On track with its strategic plans; successfully completed proof of concept for ApoTainerTM; sufficient cash to support clinical and preclinical trials; price target unchanged
Company: Cellect Biotechnology Ltd.
Report type: Annual 2017, Q1-2018 and 12 mos. Since Initiation Updates
Published on: 30 May, 2018